The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects
Authors:
- Anne B. TietzATAnne B. Tietz
- Klaus G. ParhoferKPKlaus G. Parhofer
- 1 September 2006
- journal article
- research article
- Published by Elsevier in Metabolism
- Vol. 55 (9) , 1149-1154
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- PPARγ-Activating Angiotensin Type-1 Receptor Blockers Induce AdiponectinHypertension, 2005
- Comparison of the Effects of Ramipril Versus Telmisartan in Reducing Serum Levels of High-Sensitivity C-Reactive Protein and Oxidized Low-Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes MellitusThe American Journal of Cardiology, 2005
- Effect of Pioglitazone on Lipids in Well Controlled Patients with Diabetes Mellitus Type 2 - Results of a Pilot StudyExperimental and Clinical Endocrinology & Diabetes, 2005
- Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ ActivityCirculation, 2004
- Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating ActivityHypertension, 2004
- Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention StudyCirculation, 2003
- Assessment of β‐cell function during the oral glucose tolerance test by a minimal model of insulin secretionEuropean Journal of Clinical Investigation, 2001
- Atorvastatin Improves Postprandial Lipoprotein Metabolism in Normolipidemic SubjectsThe Journal of Clinical Endocrinology & Metabolism, 2000
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985